Scarica l'app Stockscreener
7.31
1.95%
0.14
Dopo l'orario di chiusura:
7.46
0.15
+2.05%
Precedente Chiudi:
$7.17
Aprire:
$7.14
Volume 24 ore:
20,520
Relative Volume:
0.31
Capitalizzazione di mercato:
$152.28M
Reddito:
-
Utile/perdita netta:
$-24.87M
Rapporto P/E:
-5.5383
EPS:
-1.3199
Flusso di cassa netto:
$-23.65M
1 W Prestazione:
+16.96%
1M Prestazione:
-8.63%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$7.08
$7.46
Intervallo di 1 settimana:
$5.90
$7.58
Portata 52W:
$5.50
$13.39
Satellos Bioscience Inc Stock (MSLE) Company Profile
Nome
Satellos Bioscience Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare MSLE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
7.31 | 149.36M | 0 | -24.87M | -23.65M | -1.3199 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Satellos Bioscience Inc Stock (MSLE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-06 | Iniziato | Leerink Partners | Outperform |
| 2026-03-11 | Iniziato | Cantor Fitzgerald | Overweight |
Satellos Bioscience Inc Borsa (MSLE) Ultime notizie
MSLE : Satellos Bioscience Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
MSLE: Satellos Bioscience Inc.Insider Transations - Zacks Investment Research
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference - Investing News Network
Satellos Bioscience to Showcase DMD Program at April Bloom Burton Healthcare Investor Conference - TipRanks
Satellos Bioscience (NASDAQ: MSLE) plans Bloom Burton investor conference presentation - Stock Titan
Satellos Bioscience (NASDAQ:MSLE) Coverage Initiated by Analysts at Leerink Partners - Defense World
Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Satellos Bioscience (NASDAQ:MSLE) Now Covered by Analysts at Leerink Partners - MarketBeat
Leerink initiates Satellos Bioscience stock with Outperform rating By Investing.com - Investing.com South Africa
MSLE Archives - 24/7 Wall St.
Leerink initiates Satellos Bioscience stock with Outperform rating - Investing.com
Satellos initiated with an Outperform at Leerink - TipRanks
Investment bank Leerink Partners recently released a research report, initiating coverage on biotechnology company Satellos Bioscience Inc. (stock symbol: MSLE) for the first time. - Bitget
Satellos Bioscience Inc. (0IT.SG) Options Chain - Yahoo! Finance Canada
All News for MSLE : Satellos Bioscience Inc. - Zacks Investment Research
What date does Satellos Bioscience Inc.'s (MSLE) report EarningsEarnings Calendar & Announcement - zacks.com
Long Term Trading Analysis for (MSCL) (MSCL:CA) - Stock Traders Daily
Brokers Offer Predictions for MSLE FY2030 Earnings - Defense World
FY2030 Earnings Forecast for MSLE Issued By HC Wainwright - MarketBeat
Dividend HistorySatellos Bioscience Inc. (MSLE) - Zacks Investment Research
Satellos Bioscience: 2025 Financial Performance - AlphaStreet
Satellos Bioscience (NASDAQ:MSLE) Releases Earnings Results - MarketBeat
Stocks in play: Satellos Bioscience Inc. - Barchart
Satellos Bioscience Posts 2025 Results, Advances SAT-3247 Into Global Phase 2 Duchenne Trials - TipRanks
Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Satellos Bioscience: Q4 Earnings Snapshot - marketscreener.com
Satellos Bioscience : Fourth Quarter 2025 Management’s Discussion Analysis - marketscreener.com
Satellos Bioscience (NASDAQ: MSLE) files annual report; 15,458,903 shares - Stock Titan
Satellos Bioscience (MSLE) funds 2027 runway while advancing Phase 2 DMD trials - Stock Titan
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress - 富途牛牛
MSLE Earnings History & Surprises | EPS & Revenue Results | SATELLOS BIOSCIENCE INC (NASDAQ:MSLE) - ChartMill
MSLE News | SATELLOS BIOSCIENCE INC (NASDAQ:MSLE) - ChartMill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Satellos Bioscience (NASDAQ:MSLE) Downgraded to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Cantor Fitzgerald Initiates Coverage on Satellos Bioscience (NASDAQ:MSLE) - Defense World
(MSCL) Comprehensive Trading Strategy Report (MSCL:CA) - Stock Traders Daily
This Canadian biotech stock will beat the market, analyst says - Cantech Letter
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Satellos Bioscience Inc. - Mena FN
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference - Bitget
Satellos Bioscience Unveils Positive Interim SAT-3247 Data in Duchenne Muscular Dystrophy at MDA 2026 - TipRanks
Interim Duchenne and FSHD data on SAT-3247 from Satellos (NASDAQ: MSLE) - Stock Titan
(MSCL) Advanced Equity Analysis (MSCL:CA) - Stock Traders Daily
Satellos prices $50M public offering - MSN
(MSCL) Technical Analysis and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Bioscience Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
(MSCL) Trading Performance and Risk Management (MSCL:CA) - Stock Traders Daily
MSCLFSatellos Bioscience Inc Latest Stock News & Market Updates - Stock Titan
(MSCL) Strategic Market Analysis (MSCL:CA) - Stock Traders Daily
Satellos Bioscience (MSLE) Stock Analysis Report | Financials & Insights - Benzinga España
Duchenne Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 75+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - StreetInsider
Satellos Bioscience Inc Azioni (MSLE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):